Cancer treatment gets $0.9 million boost
Israel’s VBL Therapeutics (reported here previously) has been awarded a grant of up to $0.9 million by the Israel Innovation Authority. It will support the Phase 3 study of VBL’s lead candidate VB-111 for the treatment of platinum-resistant ovarian cancer.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink